INTRAVITREAL RANIBIZUMAB TREATMENT FOR ADVANCED FAMILIAL EXUDATIVE VITREORETINOPATHY WITH HIGH VASCULAR ACTIVITY.

Journal: Retina (Philadelphia, Pa.)
Treatment Used: Intravitreal Ranibizumab (IVR)
Number of Patients: 20
MediFind Summary

Overview: This study evaluated the effectiveness of intravitreal (delivered into the vitreous humor of the eye) ranibizumab (IVR) treatment for advanced familial exudative vitreoretinopathy (genetic disorder affecting the growth and development of blood vessels in the retina of the eye) with high vascular (blood vessel) activity.

Conclusion: Intravitreal (delivered into the vitreous humor of the eye) ranibizumab treatment may effectively regress advanced familial exudative vitreoretinopathy (genetic disorder affecting the growth and development of blood vessels in the retina of the eye) with high vascular (blood vessel) activity in select cases.

Abstract

Objective: To determine the efficacy of intravitreal ranibizumab (IVR) treatment for advanced familial exudative vitreoretinopathy with high vascular activity.

Methods: The retrospective interventional case series included 28 eyes (20 patients) that had IVR in combination or not with other treatment, for Stage 3 to 5 familial exudative vitreoretinopathy with active fibrovascular proliferation and prominent subretinal exudation. Outcome measures were fundus features after treatment, associated clinical variables, and genetic mutations.

Results: The age of patients at the first IVR ranged from 0.2 to 36 months. An average of 1.3 IVR injections per eye were given. Familial exudative vitreoretinopathy regressed in 16 (57%) eyes and progressed in 12 eyes (43%) after IVR. Laser and/or vitrectomy was performed on 13 eyes. The retina was reattached in 22 eyes (78%) after 24 to 58 months follow-up. Clinical variables associated with progression after IVR were preexisting fibrovascular proliferation over one quadrant and persistent vascular activity after the initial injection (P < 0.05). Familial exudative vitreoretinopathy-causative genetic mutations in 11 patients were related to variable response to IVR treatment.

Conclusions: Intravitreal ranibizumab treatment may effectively regress advanced familial exudative vitreoretinopathy with high vascular activity in selected cases. Different treatment outcomes may be relevant to variable presentation and genetic heterogeneity of familial exudative vitreoretinopathy.

Similar Latest Advances